The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
Information source: University of Aarhus
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Osteogenesis Imperfecta
Intervention: Zoledronic acid (Drug); Teriparatide (Drug); placebo zoledronic acid (Drug); placebo teriparatide (Drug)
Phase: Phase 2
Status: Recruiting
Sponsored by: University of Aarhus Official(s) and/or principal investigator(s):
Bente Langdahl, MD, Principal Investigator, Affiliation: Aarhus University Hospital
Overall contact:
Bente Langdahl, Phone: 0045 7846 7678, Email: bente.langdahl@aarhus.rm.dk
Summary
Osteogenesis imperfecta (OI) is an inherited disease of the connective tissue. Symptoms are
fractures, growth retardation, blue sclera, bad teeth, impaired hearing a. o. The aim of the
present study is to investigate the effect of treatment of adult OI patients with
bisphosphonate (zoledronic acid), parathyroid hormone (PTH) or placebo on bone mass,
fracture risk and quality of life.
The investigators will therefore conduct a double blind, placebo controlled trial, taking
genotype and previous antiresorptive therapy into account.
Clinical Details
Official title: The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
Primary outcome: Bone Mineral Density (BMD)
Secondary outcome: Fracture risk
Eligibility
Minimum age: 22 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- clinical diagnosis of osteogenesis imperfecta
- BMD<-2. 0 or
- BMD<-1 and significant fracture within 3 years
- women postmenopausal or using accepted contraception
Exclusion Criteria:
- creatinine clearance <30mL/min
- treatment with glucocorticoids > 5mg daily during the last 3 months
- metabolic bone disease or vitamin d deficiency
- liver or kidney disease
- contradictions to zoledronic acid or teriparatide
- increased baseline risk of osteosarcoma
Locations and Contacts
Bente Langdahl, Phone: 0045 7846 7678, Email: bente.langdahl@aarhus.rm.dk
Department of endocrinology, Hvidovre 2650, Denmark; Recruiting
Jens-Erik B Jensen, Email: Jens-Erik.Beck.Jensen@hvh.regionh.dk
Jens-Erik B Jensen, Sub-Investigator
Department of Endocrinology M, Odense 6000, Denmark; Recruiting
Lars Folkestad, Email: lfolkestad@health.sdu.dk
Lars Folkestad, Sub-Investigator
Osteoporosis clinic; department of endocrinology and metabolism, Aarhus, Aarhus C 8000, Denmark; Recruiting
Jannie Hald, Phone: 0045 7846 7686, Email: janniehald@gmail.com
Jannie Hald, Sub-Investigator
Additional Information
Starting date: November 2012
Last updated: May 28, 2015
|
